Pincer 12th sept2014 1

Academic Department of Critical Care Queen Alexandra Hospital Portsmouth

Hot Topics in ICM

Steve Mathieu Consultant in Intensive Care Medicine Queen Alexandra Hospital, Portsmouth

12th September 2014

Hot Topics/QuesCon spoDng

•  Syllabus •  Examiners report

•  Review arCcles & key papers – JICS •  Guidelines •  Review FICM & ICS websites

•  CriCcal Eye •  Other resources


Any dodgy ones?

Examiners Report April/May 2014

hRp://www.ficm.ac.uk/sites/default/files/document-‐files/EXM-‐FFICM-‐Summary-‐ChairmanReport-‐April2014_0.pdf

FFICM

March 2013

April 2014


Original Ar4cles Reviews Case reports CAT reviews Others

July 2014 Echo in PE Quality (pressure ulcers)

DKA Acute mesenteric ischaemia

Epidural abscess JW GI haemorrhage Mixed OD Acromegaly

StaCn & VAP SEPSISPAM ProtecCve venClaCon in abdominal surgery Heart rate control in sepCc shock

Delirium

April 2014

Tracheostomy VAP Improving Cmeliness of Cme-‐criCcal transfers

HIT HepaCCs B & C SedaCon Electrical muscle sCmulaCon in ICU (CIPN)

HD for dabigatran associated coagulopathy Wernickes PaCent with tetanus

TBI Hope ICU (delirium) CSL or HES TTM

Prone venClaCon Capnography

Jan 2014 COMET-‐UK (CO monitoring) Tracheostomy

Right heart failure StabilisaCon and transport of criCcally ill child

ECG and trauma Rhabdomyolysis PancreaCCs MDMA toxicity Hyperthyroidism Pulmonary haemorrhage and AKI

TracMan AKI Organ donaCon Surveillance for VAP PE supplement

October 2013

Echo NAVA venClaCon Pain Brainstem tesCng

Plasma exchange in HUS Intralipid in felodipine toxicity Tracheostomy

Transfusion strategies for upper GI bleed Prone TXA

Survey on rehab aeer criCcal illness Echo in UK Blood transfusion in ICU BIS monitoring Faecal inconCnence in ICU

July 2013 Noise level in ICU (delirium)

Serious Hazards of Transfusion (SHOT) Medical support for heart failure PCT NO

OTC deficiency Hyperkalaemia in HIV paCent with ‘PCP’

ICP monitoring SedaCon

Gentamycin & vancomycin Ancillary tests in diagnosis of brainstem tesCng LCP

Guidelines


Standards -‐ quality •  Staffing

–  Consultant presence

•  24/7 & within 30 minutes –  Consultant: paCent 1:8 – 1:15; ICU resident/

paCent 1:8

–  Designated CD –  Ward rounds x2 daily –  Training / FICM / Board Tutors –  Nursing 1:1 (level 3); 1:2 (level 2)

–  MDT e.g. physio, pharmacy, dieCcians •  Opera4onal

–  Large ICUs divided into pods of 8-‐15 paCents

–  Admit within 4 hrs of decision to admit –  Avoid non-‐clinical transfers –  Transfer to ward – clear and formalised –  Out of hours transfers

–  Readmission within 48 hours bad –  Assessment of rehab for each paCent

•  Equipment

–  Training •  Data Collec4on

–  ICNARC –  Risk register


NCEPOD 2014: Tracheostomy •  DocumentaCon & consent

–  IndicaCons, type, inner tube, reasons for failed extubaCon/why no trial of extubaCon

•  Different types of tubes

•  Rapidly available difficult airway trolley

•  Training programmes in blocked/displaced tubes

•  Capnography

•  Discharge of paCents with tracheostomy

•  MDT – physio & SALT


Tracheostomy standards ICS

•  IndicaCons for tracheostomy

•  CauCons and contraindicaCons

•  Consent

•  Equipment •  Ultrasound

•  Anaesthesia

•  Staffing

•  Types of tracheostomy tubes

•  Inner cannulae •  ComplicaCon

–  Early

–  Late

–  Airway emergencies

Guidelines

•  Blood transfusion –  ABLE MulCcentre UK RBC transfusion (7d vs. 15-‐25d)

–  Transfusion triggers – TRICC & Villaneuva

–  Guidelines on the management of anemia and RBC transfusion in adult criCcally ill paCents

h"p://www.bcshguidelines.com/documents/BCSH_Cri;cal_Care_Guidelines_Final_Version_22_10_12.pdf

–  Serious Hazards of Transfusion (SHOT) – JICS July 2013

•  CalculaCon of Cerebral Perfusion Pressure •  AF management – NICE & JICS

•  Clinical Guidelines on management of pain, agitaCon and delirium



•  Transfusion Triggers

•  Blood conservaCon •  Pre-‐transfusion clinical assessment •  Rate of transfusion/fluid balance •  InvesCgaCon adverse events •  Storage duraCon



CCM 2013

Some guidelines


ConsultaCons


CriCcal Eye No 6:

Core standards

Examiners report

No 5:

FICM ConsultaCons:

IV fluids

(NICE – IV therapy in adults in hospital Dec 2013)

Head injury & specialist centres

Quality – quality indicators?

No 4:

1st Examiners report – March 2013

The key papers in CriCcal Care


NAP 4 -‐ 2011

•  All NHS hospitals for 1 year ’08-‐’09 •  184 reports

"  133 anaesthesia "  36 ICU "  15 ED

•  Inclusion criteria "  death, brain damage "  emergency surgical airway

"  unanCcipated ICU admission "  ProlongaCon ICU stay


Summary of NAP 4

"   25% of major airway events in a hospital occur in ICU or the ED

"   46% of ICU events and 53% of ED events occurred out of hours

"   50% of ICU events were due to tracheostomy related events

"   50% events in ICU and 27% events in ED resulted in death

"   61% events in ICU resulted in death or severe neurological harm


RecommendaCons

"   Capnography "   Airway equipment "   Back up planning "   Staffing "   PaCent transfers "   EducaCon/training "   Tracheostomy tube design "   Team working


TracMan •  909 intubated paCents •  Respiratory failure

–  < 4 days –  Predicted to need MV for further 7 days

•  Tracheostomy Cming

•  Early (≤ 4 days) vs late (aeer 10 days)

•  No difference in –  30/7Mortality; ICU LOS; ComplicaCons

•  Only 45% late group received trache


OSCAR

•  795 paCents with moderate -‐ severe ARDS (<26.7kPa / 200mmHg)

•  CMV vs. HFOV (MV <7 days) •  No difference in

–  30/7 mortality (41%)

–  DuraCon anCmicrobial agents (2/3 chest sepsis)

–  VasoacCve support duraCon –  ICU LOS –  Hospital LOS


OSCILLATE •  548 paCents with moderate -‐ severe

ARDS

•  HFOV vs low Vt/High PEEP CV (MV < 3d) •  Trial stopped early as harm with HFOV

•  HFOV –  Hospital mortality 47% vs 35%

–  More sedaCon

–  More NMBA’s

–  More vasopressors



OSCAR OSCILLATE

29 ICU’s UK 39 ICU’s 5 countries

795 paCents 548 paCents (planned 1200)

PaO2:FiO2 < 200mmHg

Bilateral pulmonary infiltrates MV for LESS than 7 consecuCve days at the point of randomisaCon

PaO2:FiO2 < 200mmHg FiO2 > 0.5 Bilateral pulmonary infiltrates MV for LESS than 3 consecuCve days at the point of randomisaCon

Encouraged to use PC 6-‐8mls/kg and use ARDS protocol for FiO2 & PEEP R 100 venClator PEEP 11

CV – PC 6mls/kg, 3100 B venClator Recruitment maneuvers before HFOV Protocol specified high PEEP for CV (PEEP 13)

30d mortality 42% vs. 41% (HFOV vs. CV) 30d mortality 40% vs. 29%

Hospital mortality 47% vs. 35% (HFOV vs. CV)

More NMBA’s More midazolam, vasoacCve drugs, NMBA’s in HFOV

Lower PEEP strategy ? recruitment maneuvers of lung before HFOV injurious

Mortality 41% in control group Mortality 35% in control group

PROSEVA •  466 paCents with severe ARDS •  Prone posiCon vs supine posiCon •  Prone posiCon was associated

with

–  Improved mortality •  28 day: 16% vs 33% •  90 day: 24% vs 41%

–  Less cardiac arrests –  No difference in complicaCons


PROSEVA


ARDS -‐ lots of trials "   HFOV "   Nitric Oxide "   Surfactant "   Perflourocarbon ""   Late steroids (LaSRS)""   Prostaglandin E1 ""   Lysophylline (LARMA)""   Ketoconazole (KARMA)

"   Streptokinase "   StaCns (HARP 2, SAILS) ""   Neutrophil elastase inhibitor "

"   ImmunonutriCon (Eden-‐Omega)"

"   rhAPC ""   Albuterol/salmeterol (BALTI I

& II, ALTA) ""   Lower Vt !"   ? Furosemide (FACTT) !"   Cisatricurium "   Prone ‘back’ in


BALTI -‐ 2012

•  162 paCents; 46 UK ICU’s •  ARDS & MV

-‐ salbutamol 15mcg/kg/hr or placebo

-‐  Treatment for up to 7 d

•  Mortality greater in those given salbutamol 34% vs 23% at 28d


StaCns in ARDS

•  MulCcentre, RCT •  RosuvastaCn vs. placebo in ARDS •  StaCn may modulate inflammatory response

•  745 paCents (trial stopped early because of fuClity)

•  Primary outcome: •  60d mortality: 28.5% vs. 24.9% (staCn vs. placebo) •  VenClator free days: 15.1 vs. 15.1


StaCn & VAP •  300 paCents with suspected VAP (CPIS

≥ 5)

•  SimvastaCn 60mg vs placebo •  No difference in –  28d survival –  ICU or hospital mortality

–  DuraCon MV –  Delta SOFA

•  Increased mortality in staCn naieve


Magnesium in asthma

•  1200 paCents 2008-‐2012 •  Neb vs. IV Mg vs. placebo •  No role for neb Mg •  Limited role at best for IV Mg

•  Not life threatening asthma

Intravenous or nebulised magnesium sulphate versus standard therapy for severe acute asthma (3Mg trial): a double-‐blind, randomised controlled trial Goodacre et al Lancet 2013 Vol 1 (4) 293-‐300



•  Meta-‐analysis

•  16 trials inc PEITHO, MAPPETT, MOPETT, TOPCOT

•  Thrombolysis + anCcoagulaCon vs. anCcoagulaCon alone

•  All cause mortality less in thrombolysis group but major bleeding & ICH higher

TTM •  950 unconscious adults; 36 ICU’s •  33°C (n=473) with 36°C (n=466) •  No difference in

–  All cause mortality 33°C (50%) with 36°C (48%)

–  poor neurological func4on at 180 days

33°C (54%) with 36°C (52%)


Pre-‐hospital hypothermia •  Prehospital cooling vs. standard care •  2L of cold normal saline once ROSC •  1,359 OOHCA paCents •  Cooling effecCve (reduced temp) •  No difference –  Survival to hospital discharge

•  VF 63% vs 64% •  nonVF 19% vs 16%

–  Good neurological recovery •  VF 57% vs 62% •  nonVF 14% vs 13%


IABP – SHOCK II •  600 paCents with cardiogenic shock

secondary to AMI

•  IABP vs no IABP •  All received early revascularisaCon

and best medical therapy

•  No difference –  30/7 mortality (40%)

–  ICU LOS, catecholamine, bleeding •  Lancet 2013 Sept – 12/12 results = no

difference in mortality or reinfarcCon rate


VSE in cardiac arrest •  268 paCents in hospital cardiac arrest •  Vasopressin(20IU/CPR cycle) +

epinephrine (1mg/CPR cycle) + methylprednisilone (40mg) vs placebo + epinephrine (1mg/CPR cycle)

•  VSE group –  ROSC at 20 mins higher 84% vs 66%

–  Improved survival to hospital discharge with CPC 1 or 2

–  Improved haemodynamics & cvSpO2

–  Less organ dysfuncCon •  and Academic Department of Critical Care

Queen Alexandra Hospital Portsmouth

SEPSIS

Ferrer: Empiric anCbioCcs in sepsis

•  RetrospecCve observaConal cohort study •  165 ICUs – Europe, US & S America •  Jan 2005-‐ Feb 2010 •  18,000 paCents with sepCc shock •  Delay in anCbioCcs administraCon over first 6 hours aeer

idenCficaCon of SS or sepCc shock -‐> increased mortality

•  < 1 hr 24.6%; 1-‐2h 25.9% > 6h 33%


SEPSISPAM

•  RCT, mulCcentre, 29 French ICUs

•  March 2010 – Dec 2011

•  SepCc shock

•  Target MAP 80-‐85 vs. 65-‐70 •  No difference in

–  28 day mortality (high MAP 36.6% vs. 34%)

•  New AF 6.7% in higher MAP group vs. 2.8% P=0.02

•  In chronic hypertension group, worsening creaCnine and need for RRT was lower in higher MAP group


OPTIMISE

•  RCT, mulCcentre, 17 UK ICUs

•  734 paCents

•  > 50y undergoing GI surgery with one or more ‘high risk’ risk factors

•  Algorithm-‐directed care dictaCng colloid and dopexamine administraCon using vs. clinician directed care without use of CO monitoring

•  Primary outcome: composite of 30d mortality and mod/major complicaCons –  IntervenCon: 36.6% –  Control arm: 43.4%

•  No SS difference in secondary outcomes –  POMS, infecCous complicaCons, criCcal care free days at 30d, mortality at 30d

and 180d, hospital LOS


PROWESS SHOCK •  Randomised, controlled, mulCcentre,

parallel group study

•  1,697 paCents with sepCc shock •  No difference in

–  28 day mortality (APC 26.4% vs 24.2%)

–  90 day mortality (34.1% vs 32.7%)

•  No subgroup effect seen in protein C deficient group

•  Serious bleeding n = 10 APC vs 8 placebo


VANISH


Vasopressin & corCcosteroids in SepCc Shock. A Pilot Study – Gordon A, 2014 HydrocorCsone

-‐ vasopressin sparing -‐ reduced duraCon vasopressin -‐ reduced dose vasopressin -‐ no effect on vasopressin levels

B blockers in sepCc shock

•  Open label, single unit •  SepCc shock + HR ≥ 95 + NADR •  77 paCents – esmolol infusion (HR

80-‐94) vs 77 paCents standard treatment

•  Esmolol group –  28d Mortality 50% vs 81% in placebo

–  Improved SV index, LVSWI, lactate

–  Less NADR requirement

–  Less fluid requirement


CirculaCon

Sepsis & EGDT

ProMISe – UK – soon…

ARISE – Australia – ESICM 2014 ProCESS – US -‐ complete


ProCESS

•  RCT 31 ICUs in US

•  03/2008 – 05/2013

•  1351 paCents with sepCc shock •  3 groups

–  EGDT –  Protocol based standard therapy –  Usual care –  No difference in 60 d mortality between groups


IVOIRE Study

•  Randomised, open study

•  18 ICU’s in France, Belgium and Netherlands 2005-‐2010

•  140 pts with sepCc shock & AKI •  HVHF 70mls/kg/hr v 35mls/kg/hr •  Slow recruitment

•  No difference in mortality = 40% 28/7 •  HVHF not recommended


Fluids •  Don’t give too much

•  Don’t give too liRle •  Make sure you give the right

amount

•  Starches bad…very bad AssociaCon of HES administraCon with mortality and AKI in criCcally ill paCents requiring volume resuscitaCon. Meta-‐analysis. JAMA 2013 vol 309 (7)

•  Albumin back in? SAFE subgroup analysis 1200 pts with severe sepsis -‐ 28/7 mortality lower in albumin group (30% vs. 35% OR 0.87)

Finfer S et al 2011 Intensive Care Med 37:86–96 Delayney metaanalysis. Role of albumin as a resuscita;on fluid for pa;ents with sepsis. 17 studies, 1977 pa;ents. Crit Care Med 2011 Albios Study – GaXnoni (video ion ESICM website)


“lets talk about fluid responsiveness”

ALBIOS

•  RCT, 100 ICUs in Italy

•  Aug 2008 – Feb 2012

•  1818 paCents with severe sepsis

•  300mls 20% HAS daily to maintain serum albumin at 30g/dl + CSL vs. CSL •  Primary outcome: mortality at 28d

–  HAS + CSL: 31.8% –  CSL: 32%

•  Secondary outcomes: 90 d mortality –  No difference


6S Study •  804 ICU pts with severe sepsis •  Compared fluid resuscitaCon

–  130/0.4 hydroxyethyl starch (tetraspan) vs Ringer's acetate

•  HES associated with –  Increased 90 day mortality

51% vs 43% –  Increased RRT requirement

22% vs 16%

–  Trend for increased bleeding 10% vs 6%


CHEST Study •  7000 ICU pts •  Fluid resuscitaCon with 6% HES

130/0.4 (Voluven) or 0.9% saline

•  No differences in – Mortality (HES 18% vs 17%) –  LOS – ICU / Hospital

•  HES associated with increased –  RRT (7% vs 5.8%; RR 1.21) –  Pruritus / Rash / HepaCc failure

-‐ Academic Department of Critical Care Queen Alexandra Hospital Portsmouth

CRISTAL Study •  2857 sequenCal ICU paCents

2003-‐2012 57 ICU’s

•  Colloids vs CSL for all fluid intervenCons other than maintenance

•  Colloids –  Reduced mortality at 28d & 90d

(25% vs 27% & 30% vs 34%)

–  More days alive without MV

–  More days alive without vasopressors

–  Less RRT

-‐



ESICM statement on colloids

1. Recommend not to use HES with mw ≥ 200kDa in paCents with severe sepsis or risk of AKI

2. Suggest avoid 6% HES or gelaCn in these groups

3. Recommend not to use colloids in paCents with head injury and not to administer gelaCns and HES in orhan donors

4. Suggest avoid hyperoncoCc soluCons for fluid resuscitaCon


Passive Leg Raise

TRAUMA

TXA "  CRASH -‐ 2 Lancet 2010 •  tranexamic acid in reducing transfusion requirements and death from significant haemorrhage following injury

•  20,000 paCents •  Risk of haemorrhage reduced by 0.8% •  No reducCon in transfusion usage •  Only 50% received blood and average only 3 (? ‘significant haemorrhage’)

"  CRASH -‐ 2 subanalysis Lancet 2011 •  Mortality directly related to haemorrhage •  Tranexamic acid only effecCve if within first 3 hours. Beyond this Cme mortality increases


TXA "  CRASH – 2 Does TXA reduce the risk of intracranial bleeding in pa4ents with TBI? BMJ 2011

•  250 of the 20,000 paCents eligible. •  Brain haemorrhage growth 5mm vs. 8mm (TXA vs. placebo) •  Not SS •  No menCon of extent of extracranial injuries in either group making mortality comparisons difficult

•  Not well matched as there were more pts with SAH (61% vs 43%)

•  No increase is focal cerebral ischaemia •  Conclusion “it is probable that benefits of tranexamic acid outweigh risks’


Trauma Haemorrhage

1. CoagulaCon monitoring and measures to support coagulaCon should be implemented early

2. Damage control surgery

3. Physiological targets, suggested use & dosing of fluids, blood products and TXA

4. PaCents on anCplatelet agents and/or oral anCcoagulants require special aRenCon

5. Mutlidisciplinary approach & evidence based protocols adapted to local circumstances need to be developed and implemented


Neuro-‐ICU

ICP Monitoring

•  MulCcentre RCT of 324 paCents Bolivia and Ecuador

•  Intraparenchymal ICP monitoring vs. clinical & imaging

•  No difference in mortality or neuropsycholoigcal status at 6/12


A Trial of Intracranial-‐Pressure Monitoring in TraumaCc Brain Injury Randall M. Chesnut et al N Engl J Med 2012; 367:2471-‐2481

Neuro

CATIS

•  4,071 paCents •  Within 48 hrs ischaemic stroke

•  nonthrombolysed and ↑BP •  Hypertension therapy vs no BP Rx •  BP control effecCve •  No difference –  death and major disability

•  14 days / hospital discharge •  3 months


INTERACT 2 •  2,839 pts with early spontaneous

intracerebral haemorrhage & ↑SBP

•  Compared SBP <140 mmHg vs <180 •  Aggressive BP control associated with –  Trend for less adverse events (p=0.06)

–  Lower modified Rankin scores

•  No difference in mortality


Magnesium for aneurysmal SAH (MASH-‐2): a randomised placebo-‐controlled trial Mees S et al. 2012 The Lancet. Vol 380 9834:44-‐49

•  8 ICU’s in Europe and S America

•  1204 paCents

•  The quesCon: does Mg reduce poor outcome by reducing vasospasm and delayed cerebral ischaemia (DCI)

•  Magnesium 64mmol/day for 20/7 or placebo

•  Primary outcome of poor outcomes as defined by score 4-‐5 on modified Rankin Scale at 3/12, or death

•  NO DIFFERENCE


Delirium

HOPE ICU •  142 paCents with delirium

•  CAM-‐ICU assessment

•  Double blinded

•  Haloperidol vs. placebo •  No change in duraCon of delirium

in criCcally ill paCents

•  Haloperidol should be reserved for short term management on acute agitaCon

Effect of intravenous haloperidol on the dura4on of delirium and coma in cri4cally ill pa4ents (Hope-‐ICU): a randomised, double-‐blind, placebo-‐controlled trial Valeirie Page. The Lancet Respiratory Medicine, Volume 1, Issue 7, Pages 515 -‐ 523, September 2013


TreaCng delerium

101 MV pa4ents RCT haloperidol vs. ziprasidone vs placebo 21/7 study period No difference in any of the groups!

The beginning; Kress NEJM 2000 ReducCon in LOS

Girard Lancet 2008 Decreased ICU stay, Cme on venClator and mortality

Strom Lancet 2010 ReducCon in LOS and venClator days No sedaCon group -‐ boluses of morphine, well established in insCtuCon, more agitated delerium in no sedaCon group

Jacob JAMA 2012 PRODEX/MIDEX No beRer than midaz or propofol at maintaining light to mod sedaCon and more adverse effects. Increased paCent interacCons. Less vent days than midazolam

Ryker JAMA 2009 ReducCon in venClator days and delirium

Mehta 2013 For MV paCents managed with protocolised sedaCon, the additon of daily sedaCon interrupCon did not reduce duraCon MV or ICU LOS

The beginning; Kress NEJM 2000 ReducCon in LOS

Girard Lancet 2008 Decreased ICU stay, Cme on venClator and mortality

Strom Lancet 2010 ReducCon in LOS and venClator days No sedaCon group -‐ boluses of morphine, well established in insCtuCon, more agitated delerium in no sedaCon group

Jacob JAMA 2012 PRODEX/MIDEX No beRer than midaz or propofol at maintaining light to mod sedaCon and more adverse effects. Increased paCent interacCons. Less vent days than midazolam

Ryker JAMA 2009 ReducCon in venClator days and delirium

Mehta 2013 For MV paCents managed with protocolised sedaCon, the additon of daily sedaCon interrupCon did not reduce duraCon MV or ICU LOS

Don’t forget the simple things….

•  Small RCT 136 paCents

•  Used NEECHAM score •  Delirium (20%) similar but less mild confusion with ear plugs and good night sleep <50% vs. 25%

Guidelines for managing delirium


GastrointesCnal

Acute UGI Bleed

•  Randomised, parallel group study

•  921 pts with severe upper GI bleeding •  Compared restricCve (Hb <7g/dL) vs liberal

transfusion strategy (Hb<9g/dL)

•  RestricCve strategy associated with

–  Reduced number of pts receiving transfusion (15% vs 51%)

–  Increased probability survival (HR 0.55) –  Less rebleeding (10% vs 16%) –  Less adverse events (40% vs 48%)


GastrointensCnal

The SuDDICU study SDD

12 meta-‐analyses of 28 RCT’s. 10 show reduced pneumonia rate; 6 show morality benefit

•  Why have clinicians avoided implemenCng it in UK?

•  What are the barriers?

•  What further evidence is required before full scale clinical implementaCon


SystemaCc review: CCM 2010

•  Those paCents receiving enteral nutriCon, stress ulcer prophylaxis may not be required and may actually increase VAP

H2R antagonists vs PPI

•  Cohort Study of 35,000 pts •  MV > 24 hours and either H2R antagonist or PPI

•  H2R antagonist group had –  Less GI haemorrhage 2.1 vs 5.9%

–  Pneumonia 27% vs 39%

–  C.Diff 2.2% vs 3.8%


Hepatology

•  ALD "   Alcohol related illness costs NHS £1.7

billion/year

"   SystemaCc review of 21 arCcles

"   Overall ICU mortality 40-‐50%

"   Mackle study only one to provide data on GI haemorrhage -‐ mortality 48%, 62%, 67%,68% for unit, hospital, 6/12 and one yr -‐ if get out of hospital most will survive

"   Organ support -‐ 3 papers (venClaCon, vasoacCve drugs, RRT)

"   Mackle -‐

-‐  if MV and vasoacCve drugs hospital mortality 86%

-‐  If MV, vasoacCve drugs and RRT > 90%

-‐  If just MV 31%

"   Saliba RRT 90%

"   Rye 100% mortality if require RRT


Intraabdominal pressures

FuncConal disability 5 years aeer ARDS

"   109 survivors from ’98 -‐ ’01

"   Interview, PFT’s, 6 min walk test, resCng & exercise oximetry, chest imaging, QOL survey

"   PFT’s normalish

"   BUT 6 min walk test 76% predicted, physical/psychological problems


Some guidelines


Suggested resources


•  JICS •  Sign up to criCcalcarereviews.com

•  Podcasts •  LITFL •  FFICM & ICS


Best of Luck!

www.wessexics.com

@WessexICS @WICSBoRomLine

@stevemathieu75

Health & Medicine

Pincer 12th sept2014 1